Healthcare Industry News: sanofi-aventis
News Release - October 9, 2006
Cardax Pharmaceuticals Appoints Fred Pashkow, MD, as EVP/CMOFormer sanofi-aventis Cardiovascular Exec to Lead Clinical and Pre-clinical Efforts
HONOLULU, Oct. 9 (HSMN NewsFeed) -- Cardax Pharmaceuticals, Inc. ("Cardax") announces the appointment of Fredric Pashkow, MD as Executive Vice President and Chief Medical Officer. He comes to Cardax from sanofi-aventis (S-A) where he most recently held the position of Vice President U.S. Medical Affairs for the Cardiovascular-Thrombosis Therapeutic Area. At S-A, he was medically responsible for all therapeutic products (released or pending release) and clinical trials focused on vascular biology, cardiovascular thrombosis/anti- platelet therapy, hypertension, and atrial fibrillation. At Cardax, he will be responsible for Pre-Clinical and Clinical Development of cardiovascular compounds in the current pipeline as well as those compounds targeting other therapeutic areas.
"I am pleased to take on these new responsibilities at Cardax," said Dr. Pashkow. "The Company's platform is a unique and exciting opportunity." As former academic cardiologist and key thought leader, Dr. Pashkow was on the staff at The Cleveland Clinic Foundation for ten years. In addition to clinical and teaching responsibilities, he was Medical Director of the Non-Invasive ("Stress") Laboratories, the Cardiac Consultation Service and the Preventive Cardiology Program.
"We are extremely fortunate to have someone of Dr. Pashkow's experience, capability, and national reputation join Cardax to lead our compounds into and through clinical trials," said David G. Watumull, CEO of Cardax. "In addition to bringing his expertise in our field, Dr. Pashkow's strong working relationship with the Company as a Board member will enable him to begin making immediate contributions to the Company as he builds our clinical program," Watumull added.
Formerly Editor-in-Chief of Heartline and Cardiac Consult, Fred is the author of textbooks and over 100 articles. One of his books was the basis of an Emmy-nominated PBS special, Women's Hearts at Risk. He has lectured internationally and has appeared on Good Morning America, Charlie Rose and the Today Show.
Fred Pashkow has also contributed to the first successful long-acting calcium channel blockers (Searle, Pfizer); several of the statin-type and other contemporary cholesterol lowering drugs (Merck, Bristol-Myers Squibb); and cardiovascular devices including the minute-ventilation pacemaker (Telectronics) and the implantable Holter monitor (Medtronic).
About Cardax Pharmaceuticals: Cardax Pharmaceuticals is a drug discovery and development company targeting large unmet medical needs where inflammation plays a crucial and often newly defined role. The Company's first product targets cardiovascular disease. Cardax Pharmaceuticals was spun out from Hawaii Biotech in May 2006.
Source: Cardax Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.